These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 31233281)

  • 21. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.
    López-Romero P; Martinez-Gamboa L; Bang H; de la Torre I; Holzkämper T; Feist E
    Arthritis Res Ther; 2020 Aug; 22(1):193. PubMed ID: 32811536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
    Tanaka Y; Ishii T; Cai Z; Schlichting D; Rooney T; Macias W
    Mod Rheumatol; 2018 Jan; 28(1):20-29. PubMed ID: 28440680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
    Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
    Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
    Takeuchi T; Genovese MC; Haraoui B; Li Z; Xie L; Klar R; Pinto-Correia A; Otawa S; Lopez-Romero P; de la Torre I; Macias W; Rooney TP; Smolen JS
    Ann Rheum Dis; 2019 Feb; 78(2):171-178. PubMed ID: 30194275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
    Emery P; Breedveld F; van der Heijde D; Ferraccioli G; Dougados M; Robertson D; Pedersen R; Koenig AS; Freundlich B;
    Arthritis Rheum; 2010 Mar; 62(3):674-82. PubMed ID: 20187135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
    van Vollenhoven R; Strand V; Takeuchi T; Chávez N; Walter PM; Singhal A; Swierkot J; Khan N; Bu X; Li Y; Penn SK; Camp HS; Aelion J
    Arthritis Res Ther; 2024 Jul; 26(1):143. PubMed ID: 39075620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of baricitinib in patients with rheumatoid arthritis.
    Honda S; Harigai M
    Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
    [No Abstract]   [Full Text] [Related]  

  • 31. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
    Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B;
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
    Zhou YZ; Zhao LD; Chen H; Zhang Y; Wang DF; Huang LF; Lv QW; Liu B; Li Z; Wei W; Li H; Liao X; Liu H; Liu X; Jin H; Wang J; Fei YY; Wu QJ; Zhang W; Shi Q; Zheng WJ; Zhang FC; Tang FL; Lipsky PE; Zhang X
    Arthritis Res Ther; 2018 Apr; 20(1):70. PubMed ID: 29636089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Peterfy C; DiCarlo J; Emery P; Genovese MC; Keystone EC; Taylor PC; Schlichting DE; Beattie SD; Luchi M; Macias W
    J Rheumatol; 2019 Aug; 46(8):887-895. PubMed ID: 30647190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.